Artiva Biotherapeutics Inc. (ARTV)

$11.77 -0.23 (-1.92%)
Market Cap N/A
Revenue (ttm) 33.49M
Net Income (ttm) -27.70M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 342,500
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associa...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 267 4467
Address:
5505 Morehouse Drive, Suite 100, San Diego, United States
Az_70
Az_70 Oct. 17 at 5:14 AM
My blue whale friend: Why don't you bear it and be patient! I mentioned this stock $ARTV when it was at $1.50 and many were attacking me and now the stock has achieved a return of over 200% - I don't mention a stock unless it goes up🏆 https://stocktwits.com/Az_70/message/619533009
0 · Reply
PaulLaurent
PaulLaurent Oct. 17 at 5:13 AM
🌅 4:00am EST Watchlist $ARTV – Next autoimmune focus: refractory RA with NK-cell platform. Plans for first-in-autoimmune study; watch design (dose, DAS28/CDAI), site timing, and any partnering updates. Steroid-sparing and combo angles in play. $AKAN – Initiative to accelerate recurring revenue via expansion up to 20 towers for high-density production. Modular footprint, improved unit economics, and phased offtakes aimed at steady B2B/B2C contracts. $KZR – Reg update on zetomipzomib in AIH plus exploring strategic alternatives (partnerships, assets, M&A). Near term: AIH study requirements, pipeline reprioritization, banker engagement. $FEMY – Will exhibit at ASRM 2025; spotlight FemaSeed, FemBloc, and diagnostics. Non-revenue event but KOL engagement and adoption catalyst; watch physician feedback and distributor interest. $BIAF – Potential multi-day runner. Monitor premarket volume, VWAP reclaims, and prior HOD retests.
0 · Reply
Nova_Trades
Nova_Trades Oct. 17 at 4:55 AM
🔥 Friday Momentum Watchlist — Part 5 🔥 $ARTV 🚀 $MIGI ⚡ $SGBX 📦 $FEMY 💊 $AKAN 🌿 Let’s finish the week strong — eyes on these for breakout moves! 📈💪
0 · Reply
BobbyWillisTrades
BobbyWillisTrades Oct. 17 at 4:07 AM
I found a stock that can go massive soon. Check out VRME🚨🚀 VRME is one of those hidden gems ready to explode soon. Compliance PR incoming next week as well. So much going on for VRME it's ready to go! VRME ✅Management announced a "treasury strategy" to boost interest income. 💎 ✅Crypto Treasure PR could drop anyday, very highly likely. ✅Strong cash position. ✅Low float https://www.youtube.com/watch?v=-WNB78MztnQ $ARTV $AKAN $KZR $ACHV ...7
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Oct. 17 at 3:56 AM
🌞 watchlist part 1 ✅ $ARTV low 6 support, if above 6.50, have potential to 6.85/7, receives FDA Fast Track designation for AlloNK in refractory rheumatoid arthritis ✅ $AKAN low 3 support, if above 3.50, have potential to 3.90/4.20 ✅ $LGCB 2.80 support, if above 3, have potential to 3.30/3.50 ✅ $KMRK low 2 support, if above 2.20, have potential to 2.50/2.70, small float ✅ $ACHV low 4 support, if above 4.50, have potential to 4.80/4.90, product pipeline in focus 🚨 The above tickers are not ideal for swing accumulation at current price ✅ Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D
0 · Reply
SR_JACK
SR_JACK Oct. 17 at 3:47 AM
🚨 $ARTV $FEMY $AKAN $ACHV $SGBX My top premarket watches for friday! 💣
0 · Reply
S2K_TP
S2K_TP Oct. 17 at 3:37 AM
🚨 PM topwatch - Oct. 17th $ARTV just ripped 122% AH. Received FDA Fast Track designation for its AlloNK® cell therapy, targeting refractory rheumatoid arthritis (RA) — a major milestone for both the company and the NK cell therapy space. If $6.00 holds PM, tape favors a squeeze toward $6.50+ $AKAN moved 51% AH, and the setup is textbook for a low-float squeeze. HTB. 3.50 break on watch PM. $KMRK up 47% AH, riding the wave of renewed interest in Asian microcaps — especially Japanese and Korean names. 2.00 hold PM could open path to 2.20 - 2.50+. $SGBX surged 26% AH. 0.5M float and HTB, short squeeze candidate. I have been watching this one for a while. 4.00 break on watch PM. $LGPS popped +23.3% on Thursday, riding the wave of speculative interest in Japanese microcaps — and the setup screams HTB squeeze. 1.30 break on watch next.
0 · Reply
Stock_Catcher
Stock_Catcher Oct. 17 at 3:00 AM
Fortune Friday Watchlist Pt. 1 $FEMY $SGBX $ARTV $MIGI $AKAN Let's Find A Big Win 🟢
0 · Reply
jamestocklover
jamestocklover Oct. 17 at 2:36 AM
$SGBX $10+ TOMORROW🔥🚀💯 $ARTV $AKAN $KMRK $KZR
0 · Reply
Fadda
Fadda Oct. 17 at 1:32 AM
$ACHV $ACON $ARTV $FEMY $KMRK
1 · Reply
Latest News on ARTV
Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update

Oct 16, 2025, 4:05 PM EDT - 9 hours ago

Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update

Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025

Aug 25, 2025, 4:05 PM EDT - 7 weeks ago

Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025

Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights

Aug 6, 2025, 4:05 PM EDT - 2 months ago

Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights

Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference

May 28, 2025, 4:05 PM EDT - 5 months ago

Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference

Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

May 13, 2025, 4:05 PM EDT - 5 months ago

Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

May 8, 2025, 8:00 AM EDT - 5 months ago

Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

Apr 28, 2025, 4:35 PM EDT - 6 months ago

Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

Apr 8, 2025, 4:05 PM EDT - 6 months ago

Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 4:05 PM EDT - 7 months ago

Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Mar 24, 2025, 4:05 PM EDT - 7 months ago

Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 20, 2025, 4:05 PM EST - 8 months ago

Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.

Jan 29, 2025, 4:05 PM EST - 9 months ago

Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.

Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 12, 2024, 4:05 PM EST - 1 year ago

Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference

Nov 11, 2024, 4:05 PM EST - 1 year ago

Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

Oct 22, 2024, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 10, 2024, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference

Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 29, 2024, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch

Aug 13, 2024, 2:14 PM EDT - 1 year ago

Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch

Artiva: Natural Killer Cell Biotech With 1st Half Of 2025 Lupus Treatment Data

Jul 22, 2024, 3:55 PM EDT - 1 year ago

Artiva: Natural Killer Cell Biotech With 1st Half Of 2025 Lupus Treatment Data

U.S. IPO Weekly Recap: Insurance And Healthcare Lead A 4 IPO Week

Jul 20, 2024, 4:50 AM EDT - 1 year ago

U.S. IPO Weekly Recap: Insurance And Healthcare Lead A 4 IPO Week

ACTU ARDT BLMZ CON LINE OS QMMM

Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering

Jul 18, 2024, 7:08 PM EDT - 1 year ago

Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering

Az_70
Az_70 Oct. 17 at 5:14 AM
My blue whale friend: Why don't you bear it and be patient! I mentioned this stock $ARTV when it was at $1.50 and many were attacking me and now the stock has achieved a return of over 200% - I don't mention a stock unless it goes up🏆 https://stocktwits.com/Az_70/message/619533009
0 · Reply
PaulLaurent
PaulLaurent Oct. 17 at 5:13 AM
🌅 4:00am EST Watchlist $ARTV – Next autoimmune focus: refractory RA with NK-cell platform. Plans for first-in-autoimmune study; watch design (dose, DAS28/CDAI), site timing, and any partnering updates. Steroid-sparing and combo angles in play. $AKAN – Initiative to accelerate recurring revenue via expansion up to 20 towers for high-density production. Modular footprint, improved unit economics, and phased offtakes aimed at steady B2B/B2C contracts. $KZR – Reg update on zetomipzomib in AIH plus exploring strategic alternatives (partnerships, assets, M&A). Near term: AIH study requirements, pipeline reprioritization, banker engagement. $FEMY – Will exhibit at ASRM 2025; spotlight FemaSeed, FemBloc, and diagnostics. Non-revenue event but KOL engagement and adoption catalyst; watch physician feedback and distributor interest. $BIAF – Potential multi-day runner. Monitor premarket volume, VWAP reclaims, and prior HOD retests.
0 · Reply
Nova_Trades
Nova_Trades Oct. 17 at 4:55 AM
🔥 Friday Momentum Watchlist — Part 5 🔥 $ARTV 🚀 $MIGI ⚡ $SGBX 📦 $FEMY 💊 $AKAN 🌿 Let’s finish the week strong — eyes on these for breakout moves! 📈💪
0 · Reply
BobbyWillisTrades
BobbyWillisTrades Oct. 17 at 4:07 AM
I found a stock that can go massive soon. Check out VRME🚨🚀 VRME is one of those hidden gems ready to explode soon. Compliance PR incoming next week as well. So much going on for VRME it's ready to go! VRME ✅Management announced a "treasury strategy" to boost interest income. 💎 ✅Crypto Treasure PR could drop anyday, very highly likely. ✅Strong cash position. ✅Low float https://www.youtube.com/watch?v=-WNB78MztnQ $ARTV $AKAN $KZR $ACHV ...7
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Oct. 17 at 3:56 AM
🌞 watchlist part 1 ✅ $ARTV low 6 support, if above 6.50, have potential to 6.85/7, receives FDA Fast Track designation for AlloNK in refractory rheumatoid arthritis ✅ $AKAN low 3 support, if above 3.50, have potential to 3.90/4.20 ✅ $LGCB 2.80 support, if above 3, have potential to 3.30/3.50 ✅ $KMRK low 2 support, if above 2.20, have potential to 2.50/2.70, small float ✅ $ACHV low 4 support, if above 4.50, have potential to 4.80/4.90, product pipeline in focus 🚨 The above tickers are not ideal for swing accumulation at current price ✅ Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D
0 · Reply
SR_JACK
SR_JACK Oct. 17 at 3:47 AM
🚨 $ARTV $FEMY $AKAN $ACHV $SGBX My top premarket watches for friday! 💣
0 · Reply
S2K_TP
S2K_TP Oct. 17 at 3:37 AM
🚨 PM topwatch - Oct. 17th $ARTV just ripped 122% AH. Received FDA Fast Track designation for its AlloNK® cell therapy, targeting refractory rheumatoid arthritis (RA) — a major milestone for both the company and the NK cell therapy space. If $6.00 holds PM, tape favors a squeeze toward $6.50+ $AKAN moved 51% AH, and the setup is textbook for a low-float squeeze. HTB. 3.50 break on watch PM. $KMRK up 47% AH, riding the wave of renewed interest in Asian microcaps — especially Japanese and Korean names. 2.00 hold PM could open path to 2.20 - 2.50+. $SGBX surged 26% AH. 0.5M float and HTB, short squeeze candidate. I have been watching this one for a while. 4.00 break on watch PM. $LGPS popped +23.3% on Thursday, riding the wave of speculative interest in Japanese microcaps — and the setup screams HTB squeeze. 1.30 break on watch next.
0 · Reply
Stock_Catcher
Stock_Catcher Oct. 17 at 3:00 AM
Fortune Friday Watchlist Pt. 1 $FEMY $SGBX $ARTV $MIGI $AKAN Let's Find A Big Win 🟢
0 · Reply
jamestocklover
jamestocklover Oct. 17 at 2:36 AM
$SGBX $10+ TOMORROW🔥🚀💯 $ARTV $AKAN $KMRK $KZR
0 · Reply
Fadda
Fadda Oct. 17 at 1:32 AM
$ACHV $ACON $ARTV $FEMY $KMRK
1 · Reply
dbr_island
dbr_island Oct. 17 at 1:32 AM
🔥 LETS END THE WEEK STRONG BULLS 🔥 If you’re reading this just know that there are opportunities to make LIFE CHANGING gains EVERY DAY Bull market, Bear market… it doesn’t matter This market lately is designed to have 100% runners almost consistently You just need to know how to play the game and be in the know BEFORE the crowd Been doing this for over 23 years so I understand market behavior You have seen the results I have changed my life Now my focus is YOU 🫵 I want to CHANGE lives I have changed many lives There is no feeling like it And I’m here to do it again I wish each one of you reading this a successful day, week, year, and beyond ❤️ $ARTV $ACON $KMRK $ACHV $FEMY see you all tomorrow!
0 · Reply
NoteToSelf5000
NoteToSelf5000 Oct. 17 at 1:25 AM
$ARTV Well worth reminding people why this has just started running in a market that the President is a specialist in causing to tank. His predecessor really wasn’t any better either! Swing policy one way, get voted out, the next one comes in spends billions canceling the previous administration’s policies blames the lack of growth on his predecessor then does the same dead growth scenario but differently! Oh sorry I forgot that what politicians do, red blue green white black orange pink with green spots on! They all have the same objective create policies that their poor deranged lives that are so far removed from the everyday person’s lives that they couldn’t possibly know what is good for the simple family man on the street! Could they foo king he ll NO!
0 · Reply
JL_TradeZ
JL_TradeZ Oct. 17 at 1:23 AM
Tomorrow’s setup looks solid with a few low-float names that still have catalysts behind them. A lot of these are sitting just under key breakout zones, so if volume shows up early, we could see some fast moves Watchlist Friday 10/17 $ARTV – FDA Fast Track catalyst and full float rotation. Needs to hold above 5.90 to confirm continuation $AKAN – Telecom tower expansion news. Ultra low float and clean technical setup under 3.50 $INDP – Microfloat biotech with cancer therapy data and strong short interest $OSRH – Completed acquisition in diabetes tech. Coiling near 0.60 with stacked EMAs $FEMY – IVF sector momentum play with strong policy catalyst and full float rotation
0 · Reply
MrSolomon
MrSolomon Oct. 17 at 12:59 AM
Picked up the following Relative Volume Alerts at close. $AKAN $FEMY $ARTV $IVF will be watching these tomorrow.
0 · Reply
TRADE_N_EAT
TRADE_N_EAT Oct. 17 at 12:41 AM
🚨 $ARTV strong after-hours close from early entries. Holding for tomorrow premarket. $AKAN $KMRK $ACHV $FEMY interesting 📊 setups for fridag oct 17 premarket. 🟢 week so far. Let close out the week strong.
0 · Reply
johns45
johns45 Oct. 17 at 12:38 AM
$ARTV Fast track status now for RA $140 million in net cash..the stock is going back to $12 easily. Great news.
0 · Reply
StockFlips
StockFlips Oct. 17 at 12:30 AM
$INDP levels 👇 4.87 / 5.25 / 7.67 / 14.31 / 24+ $IVF $FEMY $ARTV bio sector on 🔥
0 · Reply
topstockalerts
topstockalerts Oct. 17 at 12:23 AM
After Hours Top Gainers $ARTV $AKAN $KMRK $KZR $ACHV
0 · Reply
MapNeeds
MapNeeds Oct. 17 at 12:06 AM
$PRAX $WHWK $ARTV $FEMY $SCNX Great rides for today ! Multiple Opportunities !!
0 · Reply
chartgenius779
chartgenius779 Oct. 17 at 12:05 AM
$ARTV the right valuation with its cash on hand is 5.29. Dump it
0 · Reply
Sivanujun15
Sivanujun15 Oct. 17 at 12:00 AM
$ARTV $ATAI Gets FDA Breakthrough Designation to BPL-003 https://www.tradingview.com/news/DJN_DN20251016009381:0/
0 · Reply
DrevanTheStillblade
DrevanTheStillblade Oct. 16 at 11:20 PM
VRME swing into next week! $2.X+++ $ARTV $AKAN $KZR $OPEN
0 · Reply